TKTessa M. Schurink-Van 'T Klooster

Tessa M. Schurink-Van 'T Klooster

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tessa M. Schurink-Van 'T Klooster has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands

    by Tessa M. Schurink‐Van ’T Klooster, Albert G. Siebers, Joske Hoes, Folkert J. van Kemenade, Johannes Berkhof, Johannes A. Bogaards, Hester E. de Melker

    Background: The first HPV‐vaccine eligible cohorts in the Netherlands will enter the cervical screening program in 2023. However, a substantial number of young women already have had a cervical sample taken before entry into the regular screening program. This study was initiated to explore early effects of HPV vaccination on detection of cytological abnormalities in cervical samples of women younger than the screening age.Methods: Results of cervical samples were obtained from the Dutch National Pathology Databank (PALGA) and were linked to the women's HPV vaccination status from the national vaccination registry (Praeventis) (N = 42,171). Occurrence of low‐grade and high‐grade squamous intraepithelial lesions or worse (LSIL and HSIL+) and high‐risk HPV positive tests (hrHPV) in the first cervical sample were compared between vaccinated and unvaccinated women by multivariable logistic regression analysis, corrected for age at cervical sampling and age of vaccination (12/13 years, ≥ = 14 years).Results: For fully vaccinated women (three‐ or two‐dose schedule), statistically significant reductions were seen for all outcomes compared to unvaccinated women (hrHPV: adjusted OR, 0.70, 95% CI, 0.63–0.79; LSIL: 0.70, 0.61–0.80; HSIL+: 0.39, 0.30–0.51).Conclusions: By linking nation‐wide registries on pathology and vaccination, we show significant beneficial early effects of HPV‐vaccination on LSIL, HSIL+, CIN3/AIS/carcinoma and hrHPV detection in young women upto 24 years of age who have a cervical sample taken before entry into the cervical cancer screening program.


  • Open Access

    Meer bewegen: doorverwijzing naar beweegactiviteiten door eerstelijnszorgverleners

    by Tessa M. Schurink-Van ’t Klooster, Anne Loyen, Karin I. Proper

    Samenvatting: Het belang van preventie in de zorg wordt steeds meer erkend. Het bevorderen van een gezonde leefstijl, waaronder meer bewegen, vormt hiervan een belangrijk onderdeel. Met dit onderzoek is inzicht verkregen in het doorverwijzen van eerstelijnszorgverleners naar beweegactiviteiten en de redenen voor het (niet) doorverwijzen van patiënten/cliënten naar beweegactiviteiten. In interviews zijn huisartsen, praktijkondersteuners, jeugdartsen en jeugdverpleegkundigen gevraagd naar redenen voor het wel/niet doorverwijzen naar beweegactiviteiten en de benodigdheden om (vaker) te verwijzen. Een online enquête onder dezelfde doelgroepen was opgezet om deze informatie te kwantificeren. Deelname aan de interviews (n = 25) en enquête (n = 100) was laag. De jeugdgezondheidszorg adviseert vaak om meer te bewegen, vooral bij kinderen met overgewicht. Huisartsen doen dat, in lijn met de kerntaken, in mindere mate en dan vooral wanneer het de klacht kan verhelpen waarvoor ze geconsulteerd worden. Eerstelijnszorgverleners verwijzen dus voornamelijk mensen met gezondheidsproblemen door en er is minder aandacht voor bewegen ten behoeve van primaire preventie. De belangrijkste redenen waarom eerstelijnszorgverleners niet doorverwijzen hangen samen met een beperkte motivatie, de financiële situatie van patiënten en gebrek aan tijd tijdens het consult. Om vaker door te verwijzen hebben zorgverleners behoefte aan een passend en betaalbaar beweegaanbod voor alle doelgroepen.


  • Open Access

    Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule

    by Tessa M. Schurink-Van 'T Klooster, Robine Donken, Rutger M. Schepp, Fiona R.M. van der Klis, Hester E. de Melker


  • Open Access

    Mumps transmission in social networks: a cohort study

    by Susan Hahné, Tessa Schurink, Jacco Wallinga, Jeroen Kerkhof, Marianne van der Sande, Rob van Binnendijk, Hester de Melker

    Mumps emerged among highly vaccinated populations in the Netherlands. This offered a unique opportunity to study mumps virus transmission. In particular the extent to which asymptomatic infections in vaccinated people contribute to ongoing mumps virus transmission is uncertain. Insight into this could help project the future burden of mumps in vaccinated populations. We therefore studied the relative infectiousness of symptomatic and asymptomatic cases. In a cohort study we followed contacts of notified mumps cases (ring 1) and contacts’ contacts (ring 2) for 40 days to ascertain symptoms of mumps and social contacts by weekly diaries and questionnaires, and mumps virus infections by taking finger stick dried blood spot specimens (DBS) that were tested for mumps-specific IgG antibodies. Mumps IgG concentrations >1500 RU/ml in a single sample, a four-fold increase in IgG antibody concentration in paired samples, or a positive oral fluid PCR were defined as recent infection. We recruited 99 contacts (40 in ring 1 and 59 in ring 2) of 10 mumps index cases. The median age of participants was 23 years (range 18–57 years), 31 (31%) were male. At study entry, DBS of 4 out of 78 (5%) participants with samples showed serological evidence of recent mumps virus infection. Three of these reported mumps symptoms. Among the 59 participants who provided DBS at the beginning and end of the follow-up period, none had serological evidence of infection during this period. Of 72 participants who provided at least one oral fluid sample, one participant (1%) who also reported mumps symptoms, was found PCR positive. Of all 99 participants, the attack rate of self-reported mumps was 4% (95% CI 1.1–10.0%). Of the 5 laboratory confirmed mumps cases, 1 reported no mumps symptoms (percentage asymptomatic 20% (95% CI 0–71%)). Compared to non-students, students had larger households and more household members who were born after 1980 (p < 0.01 and <0.01, respectively). We demonstrated that this prospective cohort study design allows for inference of the proportion of asymptomatic mumps infections. Because we only detected one asymptomatic mumps virus infection, we could not assess the relative infectiousness of asymptomatic mumps. Household characteristics of students differed from non-students. This may partly explain recent mumps epidemiology in the Netherlands.


  • Open Access

    Immune responses after two- versus three-doses of HPV vaccination up to 4½ years post vaccination: an observational study among Dutch routinely vaccinated girls (HPV2D)

    by Robine Donken, Tessa M. Schurink-Van 'T Klooster, Rutger M. Schepp, Fiona R. M. van der Klis, Mirjam J. Knol, Chris J. L. M. Meijer, Hester E. de Melker

    In 2014 the Netherlands switched from 3 to 2 doses for routine vaccination with the prophylactic bivalent human papillomavirus (HPV) vaccine. The current study explored whether antibody responses are noninferior after 2 versus 3 doses in girls. Girls vaccinated at 12 years of age with 2 (at 0 and 6 months) or 3 doses (at 0, 1, and 6 months) of the bivalent HPV vaccine were identified in the vaccination registration system. Type-specific antibody concentrations and avidity against HPV-16/18/31/33/45/52/58 were assessed. Analyses were stratified for time since the first dose (0–2, 2–3, 3–4, or 4–4½ years). Noninferiority (margin, 0.5) of the 2- versus the 3-dose schedule in girls was examined. Geometric mean concentrations (GMCs) for vaccine types were only noninferior for 2 versus 3 doses for HPV-18 (at 2–3 years after the first dose; GMC ratio, 0.89; 95% confidence interval, .57–1.38) For vaccine types and cross-protective types (HPV-16/18/31/33/45), the avidity index was noninferior for the 2-dose compared with the 3-dose schedule, except for HPV-31 at 4–4½ years after the first dose and HPV-33 at 3–4 and 4–4½ years. GMCs for HPV-16/18 were not noninferior for 2 versus 3 doses, except for HPV-18 (at 2–3 years after first dose). However, antibody avidity for these types showed noninferiority, independent of concentrations.


  • Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infection

    by Sigrid Gouma, Hinke I. Ten Hulscher, Tessa M. Schurink-Van ’T Klooster, Hester E. de Melker, Greet J. Boland, Patricia Kaaijk, Cécile A.C.M. van Els, Marion P.G. Koopmans, Rob S. van Binnendijk


  • Open Access

    Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands

    by T. M. Schurink-Van’t Klooster, M. A. J. de Ridder, J. M. Kemmeren, J. van der Lei, F. Dekker, M. Sturkenboom, H. E. de Melker

    Since the introduction of the bivalent human papilloma virus (HPV) vaccine in the Netherlands, migraine has been reported as a notable event in the passive safety surveillance system. Research on the association between HPV vaccination and migraine is needed. Therefore, potential migraine cases in 2008–2010 were selected from a group of general practitioners and linked to the vaccination registry. Data were analysed in three ways: (i) incidences of migraine postvaccination (2009/2010) were compared to pre-vaccination incidences (2008); (ii) in a cohort, incidence rates of migraine in vaccinated and unvaccinated girls were compared and (iii) in a self-controlled case series analysis, the relative incidence of migraine in potentially high-risk periods was compared to non-high-risk periods. Incidence rates of migraine for 12- to 16-year-old girls and boys postvaccination were slightly higher than pre-vaccination incidence rates. Incidence rate ratios (IRRs) for vaccinated compared to unvaccinated girls were not statistically significantly higher. Furthermore, the RR for migraine in the high-risk period of 6 weeks following each dose versus non-high-risk period was 4.3 (95% confidence interval (CI) 0.69–26.6) for certain migraine. Conclusion: Using different methods, no statistically significant association between HPV vaccination and incident migraine was found. However, the number of cases was low; to definitively exclude the risk, an increased sample size is needed.